Delivery Order SPE2DB22D2007-SPE2DB25FJ3MT
- Not listed
- The Defense Logistics Agency awarded a $4,049.61 delivery order to AmerisourceBergen Drug Corp on September 2, 2025, for the supply of Ingrezza 60 mg capsules (30-count units). This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of September 23, 2025. The contract is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order valued at $4,027.70 to AmerisourceBergen Drug Corp for the supply of Ingrezza 80 mg capsules (30-count units) under a firm fixed price contract. The award was issued on September 18, 2025, with an ultimate completion date of October 9, 2025. This non-competitive delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at...
- The Defense Logistics Agency awarded a delivery order valued at $3,676.12 to AmerisourceBergen Drug Corp on August 21, 2025, for the supply of Ingrezza 40 mg capsules (30-unit quantity). This competitively awarded, firm fixed-price delivery order is scheduled for completion by September 12, 2025, with performance taking place at the contractor's facility in Conshohocken, Pennsylvania. The contract contains no set-aside designation, reflecting AmerisourceBergen's demonstrated capability to...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Ingrezza 80 mg capsules (30-count units) under a firm fixed price contract valued at $4,027.70, with an ultimate completion date of August 15, 2025. This non-competitive delivery order was issued on July 25, 2025, with performance based in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. The award represents a child order under the company's larger...
- The Defense Logistics Agency awarded a $3,676.12 delivery order to AmerisourceBergen Drug Corp for the supply of Ingrezza 40 mg capsules (30-count) under a firm fixed price contract. The award was issued on July 24, 2025, with an ultimate completion date of August 14, 2025, and performance will be executed at the contractor's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a non-competitive, non-set-aside award and is characterized as a child contract,...
- The Defense Logistics Agency awarded a $8,077.31 delivery order to AmerisourceBergen Drug Corp on September 18, 2025, for the supply of Ingrezza 60 mg capsules (30-count units). This competitively awarded, firm fixed-price contract is scheduled for completion by October 9, 2025, with performance taking place at the contractor's corporate office in Conshohocken, Pennsylvania. The award represents a child delivery order under AmerisourceBergen's broader pharmaceutical supply relationship with DLA....
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 16, 2025, for the supply of Ingrezza 40 mg capsules (30-count units) valued at $3,676.12. This competitively awarded, firm fixed-price delivery order is scheduled for completion by October 7, 2025, and will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award carries no set-aside designation, reflecting the contractor's demonstrated capability to...
- The Defense Logistics Agency awarded a delivery order contract to AmerisourceBergen Drug Corp on August 21, 2025, for the supply of Ingrezza 40 mg capsules (quantity: 30 units) with a ceiling value of $14,704.48. This is a firm fixed-price delivery order with an ultimate completion date of September 12, 2025, and represents a non-set-aside competitive award. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 9, 2025, for the supply of Ingrezza 80 mg capsules (30-count units) with a ceiling value of $4,027.70 and a firm fixed price structure. This order is set to be completed by July 30, 2025, and represents a competitive award with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location, leveraging its...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Ingrezza 40 mg capsules (30-count units) valued at $3,676.12. This firm fixed-price delivery order, issued on June 16, 2025, is scheduled for completion by July 9, 2025, with performance occurring at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The award represents a non-competitive delivery order executed under an existing contract vehicle, reflecting the agency's...
- SPE2DB22D2007Indefinite Delivery Contract
- SPE2DB22D2007-SPE2DB25FJ3MTDelivery Order
The Defense Logistics Agency awarded a $3,676.12 delivery order to AmerisourceBergen Drug Corp on July 31, 2025, for the supply of Ingrezza 40 mg capsules (30-count units). The contract, which is not set-aside, carries a firm fixed price structure with an ultimate completion date of August 21, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform this delivery order from its corporate office location. This award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026, which serves as a comprehensive pharmaceutical support vehicle for military healthcare systems worldwide. Ingrezza is a neurological medication used in the treatment of involuntary movement disorders. This delivery order demonstrates AmerisourceBergen Drug Corp's continued role as a critical pharmaceutical distributor for federal medical procurement, particularly supporting military and veteran healthcare systems. The company's competitively awarded contracts with DLA span a broad therapeutic portfolio including specialty medications, vaccines, and medical supplies, positioning it as a key vendor within the federal medical supply chain and the broader Pharmaceutical Prime Vendor Global Program.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.7k | 7/31/25 |